Global law firm DLA Piper has advised international veterinary pharmaceuticals company Dechra Pharmaceuticals PLC on the proposed acquisition of Apex Laboratories Pty Ltd, valued at AU$55 million.

The DLA Piper team was led by Corporate partner David Ryan and senior associate James McCarthy, with assistance from Intellectual Property partner Melinda Upton, Head of Employment Nicholas Turner and solicitor Lauren Crossman.

David Ryan said: "We're delighted to have advised Dechra on the acquisition of Apex, with its complementary portfolio offering. The transaction will enable our client to expand their presence in the growing Australasian and Asian veterinary pharmaceutical and animal product markets."

Established in 1962, privately owned Apex is Australia's leading manufacturer of generic and proprietary veterinary pharmaceuticals and pet care products for the Australian and New Zealand markets.

The acquisition is expected to be complete in mid-October, and includes the purchase of Apex's manufacturing site.